The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Blomensy 15 mg film-coated tablets

EGIS Pharmaceuticals PLCPA1470/006/003

Main Information

Trade NameBlomensy 15 mg film-coated tablets
Active SubstancesRivaroxaban
Dosage FormFilm-coated tablet
Licence HolderEGIS Pharmaceuticals PLC
Licence NumberPA1470/006/003

Group Information

ATC CodeB01AF01 rivaroxaban


License statusAuthorised
Licence Issued06/01/2023
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back